2022
DOI: 10.1002/jlb.5mr0622-483r
|View full text |Cite
|
Sign up to set email alerts
|

Immunotherapy targeting mesothelin in acute myeloid leukemia

Abstract: Mesothelin (MSLN) is an emerging target that exists in soluble and membrane‐associated forms. It is usually used for the diagnosis and treatment of MSLN‐positive solid tumors. Interestingly, recent studies have shown that MSLN is highly expressed in 36% of acute myeloid leukemia (AML) patients and barely expressed in normal hematopoietic cells, which makes MSLN a promising target for the treatment of AML. It has been shown that MSLN is detectable as a diagnostic marker in its soluble form. Although the mechani… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 74 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?